PATENT CLAIM ANALYSIS

Application Number: 15743349
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "04400A"]

Abstract:
The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the insulin-like growth factor binding protein, acid labile subunit (IGFALS) gene or the insulin-like growth factor 1 (IGF-1) gene, methods of using such double stranded RNAi agents to inhibit expression of an IGFALS gene or an IGF-1 gene, and methods of treating subjects having an IGF system-associated disorder.

Claim (Index 117):
The method of  claim 116 , wherein the at least one sign or symptom of acromegaly is selected from the group consisting of elevated IGF-1 level, somatic enlargement, excessive sweating, jaw overgrowth, sleep apnea, osteoarthropathy, joint pain, symptomatic carpal tunnel syndrome, hypertension, biventricular cardiac hypertrophy, cardiac arrhythmia, fatigue, weakness, diabetes mellitus, menstrual irregularities in women and sexual dysfunction in men, headache, visual field loss attributable to optic chiasmal compression, and diplopia due to cranial nerve palsy; in conjunction with an elevated growth hormone level.

Metadata:
- Claim Count in Document: 65.0
- Percentile: 86.0
- Lexical Diversity: 1.67442
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15399820', '14976261', '14947025', '14650128', '15670132']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8382927663959407
- 35 USC 102 Novelty (BERT): 0.5431591038628188
- Combined Prediction Score: 0.8087794001426286
- Mean Citation Score: 412.498488
- Max Citation Score: 416.99576
- Similarity Product: 209.2573209851313

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test